Assuta Medical Center — Oncology | Tel Aviv, Israel

Assuta Medical Center forms part of an established private hospital network in Israel, with oncology care among its clinical services. This profile concerns Tel Aviv; network-wide capabilities should not automatically be interpreted as services available in every building or department. The exact treating hospital should appear in any proposed care plan.

The network has a substantial presence in Israeli private healthcare. Its broader history and scale provide organisational context, but do not establish the experience of an individual cancer programme. No founding date, oncology bed count or annual patient volume is asserted here because those details have not been verified for this service.

Assuta is known for access to senior consultants, some of whom also practise in public academic centres. Such appointments can bring academic and specialist experience into private care, but patients should establish who will lead treatment and whether their case will receive multidisciplinary review.

The supplied profile highlights prompt coordination of diagnostics and surgery, alongside Russian-speaking support. These are service characteristics rather than guarantees: scheduling depends on clinical urgency, specialist availability, investigations and financial authorisation. Patients needing several treatment modalities should ask how departments coordinate decisions and handovers.

The reported specialty range includes breast, lung, colorectal and prostate cancers. For these conditions, a useful assessment brings together tumour pathology, staging and relevant biomarkers rather than relying on the organ diagnosis alone. Depending on the case, planning may involve surgeons, medical oncologists, radiation oncologists, radiologists and pathologists. Patients should ask about experience with their particular subtype and stage, especially for uncommon presentations or cancer that has returned after treatment.

Blood cancers are also included in the supplied profile. However, this does not establish that every haematological treatment pathway is available at the Tel Aviv site. Patients with leukaemia, lymphoma or myeloma should confirm access to the relevant specialist service and inpatient support. Stem-cell transplantation, cellular therapies and other highly specialised procedures should not be assumed available without explicit confirmation.

Surgery is among the reported treatment options. Suitability depends on the cancer's extent, the operation's purpose and the patient's fitness. Before proceeding, clarify whether surgery is intended to cure disease, reduce tumour burden or relieve symptoms, and ask about pathology reporting, postoperative care and management of complications.

Radiation therapy is also listed. The appropriate technique and schedule depend on tumour location, previous radiation exposure and treatment goals. Patients should confirm the treatment location, planning requirements and anticipated number of visits. Particular technologies or shortened schedules should not be assumed available or suitable without specialist assessment.

Systemic treatments include chemotherapy, immunotherapy and targeted therapy. These medicines serve different purposes and are not interchangeable. Eligibility may depend on biomarkers, organ function, previous treatment and the evidence for a particular cancer subtype. Ask whether the proposed regimen is standard care, an off-label use or part of a clinical trial, and how side effects will be monitored.

Precision oncology uses tumour characteristics, including molecular findings where relevant, to inform decisions. Testing does not necessarily identify an actionable alteration or provide access to a matched medicine. Clarify why a test is recommended, whether existing results can be used and whether its findings could realistically change treatment.

The supplied profile reports around 40 active oncology clinical trials. This figure is indicative: study status changes, and an active study may no longer be recruiting. It is also important to establish whether the number refers to the Tel Aviv service or the wider network. The figure alone does not indicate which cancers, treatment stages or trial phases are represented.

International patients can ask the treating team or research office to screen their records against currently recruiting protocols. Eligibility may involve central pathology review, molecular testing, previous-treatment limits and fitness criteria. Before travelling, request the study identifier, a preliminary eligibility opinion and clarification of residency or follow-up requirements. Trial participation is voluntary and does not guarantee benefit. Distinguish research-funded procedures from routine care, travel and other expenses that remain the patient's responsibility.

Start with a remote records review where available, rather than assuming that an in-person visit will lead directly to treatment. Request a proposed sequence of assessment, investigations and decision-making, with the responsible consultant identified. If speed is a priority, ask what can be arranged provisionally and what must await pathology review, clinical examination or payment approval. Avoid committing to non-refundable travel solely on the basis of a general service description.

Plan for continuity as well as the initial intervention. Establish who handles urgent problems during the stay, whether hospital admission is available when needed and how the home oncology team will receive results. Obtain a written discharge or treatment summary, medicine instructions and a follow-up schedule. Fitness to fly, the need for a companion and the possible duration of a stay require individual clinical advice.

Contact details below come from the hospital's own published international patient information.

Location: Tel Aviv, Israel

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +972 3 764 4444

Website: https://www.assuta.co.il

Languages supported: Hebrew, English, Russian, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.